Literature DB >> 25972164

Sp3/REST/HDAC1/HDAC2 Complex Represses and Sp1/HIF-1/p300 Complex Activates ncx1 Gene Transcription, in Brain Ischemia and in Ischemic Brain Preconditioning, by Epigenetic Mechanism.

Luigi Formisano1, Natascia Guida2, Valeria Valsecchi3, Maria Cantile3, Ornella Cuomo3, Antonio Vinciguerra3, Giusy Laudati3, Giuseppe Pignataro3, Rossana Sirabella2, Gianfranco Di Renzo3, Lucio Annunziato4.   

Abstract

The Na(+)-Ca(2+) exchanger 1 (NCX1) is reduced in stroke by the RE1-silencing transcription factor (REST), whereas it is increased in ischemic brain preconditioning (PC) by hypoxia-inducible factor 1 (HIF-1). Because ncx1 brain promoter (ncx1-Br) has five putative consensus sequences, named Sp1A-E, for the specificity protein (Sp) family of transcription factors (Sp1-4), we investigated the role of this family in regulating ncx1 transcription in rat cortical neurons. Here we found that Sp1 is a transcriptional activator, whereas Sp3 is a transcriptional repressor of ncx1, and that both bind ncx1-Br in a sequence-specific manner, modulating ncx1 transcription through the Sp1 sites C-E. Furthermore, by transient middle cerebral artery occlusion (tMCAO) in rats, the transcriptional repressors Sp3 and REST colocalized with the two histone-deacetylases (HDACs) HDAC1 and HDAC2 on the ncx1-Br, with a consequent hypoacetylation. Contrarily, in PC+tMCAO the transcriptional activators Sp1 and HIF-1 colocalized with histone acetyltransferase p300 on ncx1-Br with a consequent hyperacetylation. In addition, in neurons silenced with siRNA of NCX1 and subjected to oxygen and glucose deprivation (OGD) (3 h) plus reoxygenation (RX) (24 h), the neuroprotection of Class I HDAC inhibitor MS-275 was counteracted, whereas in neurons overexpressing NCX1 and subjected to ischemic preconditioning (PC+OGD/RX), the neurotoxic effect of p300 inhibitor C646 was prevented. Collectively, these results demonstrate that NCX1 expression is regulated by the Sp3/REST/HDAC1/HDAC2 complex in tMCAO and by the Sp1/HIF-1/p300 complex in PC+tMCAO and that epigenetic intervention, by modulating the acetylation of ncx1-Br, may be a strategy for the development of innovative therapeutic intervention in stroke.
Copyright © 2015 the authors 0270-6474/15/357332-17$15.00/0.

Entities:  

Keywords:  REST\NRSF; acetylation; brain ischemia; epigenetic; ischemic brain preconditioning; sodium/calcium exchanger

Mesh:

Substances:

Year:  2015        PMID: 25972164      PMCID: PMC6705442          DOI: 10.1523/JNEUROSCI.2174-14.2015

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  72 in total

Review 1.  The Sp-family of transcription factors.

Authors:  G Suske
Journal:  Gene       Date:  1999-10-01       Impact factor: 3.688

Review 2.  A tale of three fingers: the family of mammalian Sp/XKLF transcription factors.

Authors:  S Philipsen; G Suske
Journal:  Nucleic Acids Res       Date:  1999-08-01       Impact factor: 16.971

3.  Sp3 is a transcriptional repressor of transforming growth factor-beta receptors.

Authors:  S Ammanamanchi; M G Brattain
Journal:  J Biol Chem       Date:  2000-10-10       Impact factor: 5.157

4.  Cooperation of Sp1 and p300 in the induction of the CDK inhibitor p21WAF1/CIP1 during NGF-mediated neuronal differentiation.

Authors:  N Billon; D Carlisi; M B Datto; L A van Grunsven; A Watt; X F Wang; B B Rudkin
Journal:  Oncogene       Date:  1999-05-06       Impact factor: 9.867

5.  Dopamine receptor regulating factor, DRRF: a zinc finger transcription factor.

Authors:  C K Hwang; U M D'Souza; A J Eisch; S Yajima; C H Lammers; Y Yang; S H Lee; Y M Kim; E J Nestler; M M Mouradian
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-05       Impact factor: 11.205

6.  Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1.

Authors:  B H Jiang; G Jiang; J Z Zheng; Z Lu; T Hunter; P K Vogt
Journal:  Cell Growth Differ       Date:  2001-07

7.  The rod cGMP-phosphodiesterase beta-subunit promoter is a specific target for Sp4 and is not activated by other Sp proteins or CRX.

Authors:  Leonid E Lerner; Yekaterina E Gribanova; Leigh Whitaker; Barry E Knox; Debora B Farber
Journal:  J Biol Chem       Date:  2002-04-09       Impact factor: 5.157

8.  The transcriptional repressor Sp3 is associated with CK2-phosphorylated histone deacetylase 2.

Authors:  Jian-Min Sun; Hou Yu Chen; Mariko Moniwa; David W Litchfield; Edward Seto; James R Davie
Journal:  J Biol Chem       Date:  2002-08-09       Impact factor: 5.157

9.  Ischemic insults derepress the gene silencer REST in neurons destined to die.

Authors:  Agata Calderone; Teresa Jover; Kyung-min Noh; Hidenobu Tanaka; Hidenori Yokota; Ying Lin; Sonja Y Grooms; Roodland Regis; Michael V L Bennett; R Suzanne Zukin
Journal:  J Neurosci       Date:  2003-03-15       Impact factor: 6.167

10.  Sp1 and Sp3 recruit histone deacetylase to repress transcription of human telomerase reverse transcriptase (hTERT) promoter in normal human somatic cells.

Authors:  Jaejoon Won; Jeongbin Yim; Tae Kook Kim
Journal:  J Biol Chem       Date:  2002-07-31       Impact factor: 5.157

View more
  40 in total

Review 1.  Unconventional Approaches to Modulating the Immunogenicity of Tumor Cells.

Authors:  Laurence Booth; Jane L Roberts; John Kirkwood; Andrew Poklepovic; Paul Dent
Journal:  Adv Cancer Res       Date:  2018-01-03       Impact factor: 6.242

2.  miR-206 Reduces the Severity of Motor Neuron Degeneration in the Facial Nuclei of the Brainstem in a Mouse Model of SMA.

Authors:  Valeria Valsecchi; Serenella Anzilotti; Angelo Serani; Giusy Laudati; Paola Brancaccio; Natascia Guida; Ornella Cuomo; Giuseppe Pignataro; Lucio Annunziato
Journal:  Mol Ther       Date:  2020-01-15       Impact factor: 11.454

3.  Discovery and validation of information theory-based transcription factor and cofactor binding site motifs.

Authors:  Ruipeng Lu; Eliseos J Mucaki; Peter K Rogan
Journal:  Nucleic Acids Res       Date:  2017-03-17       Impact factor: 16.971

4.  HDAC4 and HDAC5 form a complex with DREAM that epigenetically down-regulates NCX3 gene and its pharmacological inhibition reduces neuronal stroke damage.

Authors:  Luigi Formisano; Giusy Laudati; Natascia Guida; Luigi Mascolo; Angelo Serani; Ornella Cuomo; Maria Cantile; Francesca Boscia; Pasquale Molinaro; Serenella Anzilotti; Vincenzo Pizzorusso; Gianfranco Di Renzo; Giuseppe Pignataro; Lucio Annunziato
Journal:  J Cereb Blood Flow Metab       Date:  2019-11-07       Impact factor: 6.200

5.  Differential effects of HDAC inhibitors on PPN oscillatory activity in vivo.

Authors:  Veronica Bisagno; Maria Alejandra Bernardi; Sara Sanz Blasco; Francisco J Urbano; Edgar Garcia-Rill
Journal:  Neuropharmacology       Date:  2019-12-23       Impact factor: 5.250

6.  Opening a New Time Window for Treatment of Stroke by Targeting HDAC2.

Authors:  Yu-Hui Lin; Jian Dong; Ying Tang; Huan-Yu Ni; Yu Zhang; Ping Su; Hai-Ying Liang; Meng-Cheng Yao; Hong-Jin Yuan; Dong-Liang Wang; Lei Chang; Hai-Yin Wu; Chun-Xia Luo; Dong-Ya Zhu
Journal:  J Neurosci       Date:  2017-06-07       Impact factor: 6.167

Review 7.  The Emerging Role of Epigenetics in Cerebral Ischemia.

Authors:  Zhiping Hu; Bingwu Zhong; Jieqiong Tan; Chunli Chen; Qiang Lei; Liuwang Zeng
Journal:  Mol Neurobiol       Date:  2016-02-19       Impact factor: 5.590

8.  Inhibition of the Epigenetic Regulator REST Ameliorates Ischemic Brain Injury.

Authors:  Kahlilia C Morris-Blanco; TaeHee Kim; Mario J Bertogliat; Suresh L Mehta; Anil K Chokkalla; Raghu Vemuganti
Journal:  Mol Neurobiol       Date:  2018-07-23       Impact factor: 5.590

Review 9.  The emerging field of epigenetics in neurodegeneration and neuroprotection.

Authors:  Jee-Yeon Hwang; Kelly A Aromolaran; R Suzanne Zukin
Journal:  Nat Rev Neurosci       Date:  2017-05-18       Impact factor: 34.870

Review 10.  Brain REST/NRSF Is Not Only a Silent Repressor but Also an Active Protector.

Authors:  Yangang Zhao; Min Zhu; Yanlan Yu; Linli Qiu; Yuanyuan Zhang; Li He; Jiqiang Zhang
Journal:  Mol Neurobiol       Date:  2016-01-07       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.